Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

Diabetes, metabolic syndrome and obesity : targets and therapy

Reprogramming NAD(+) homeostasis and FOXO3a-Nrf2 signaling mitigates bleomycin-driven pulmonary fibrosis.

Toxicology and applied pharmacology

Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.

The Annals of pharmacotherapy

Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model.

PloS one

Plain language review: non-invasive screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in primary care.

Postgraduate medicine

Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.

Missouri medicine

Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.

JCEM case reports

Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.

Frontiers in endocrinology

$HIMS thesis is increasingly becoming: international expansion + peptides After the branded GLP-1 shift, the focus shifted to • Consumer flywheel • International expansion + M&A • New categories like peptides International growth is accelerating fast. In Q2: • $131M • https://t.co/IyXwlEgceV

Is there a stronger signal that peptides are going mainstream than a ~$8B NYSE-listed gym chain administering compounded peptides at seven of its clubs and its CEO saying he's not waiting for the FDA? That's Life Time, on its last earnings call. Life Time is the strongest https://t.co/H3OC6egPZg

There’s one thing I think the market is not looking at deeply enough when it comes to PeptAI @BioProtocol AI x Drug Discovery is not a new narrative. But an AI agent running an end-to-end drug discovery process, making each step of the experiment transparent, taking the https://t.co/jWD8hUanfy

Retatrutide just made being fat a choice. Retatrutide is a triple GLP agonist that hits GLP-1, GIP, and glucagon receptors simultaneously. Clinical trials show 24% average weight loss over 48 weeks. For reference: Retatrutide: -24.2% weight loss at week 48 Semaglutide: −14.9% https://t.co/lajGQczZP0

cagrilintide is the only peptide I'd take for fat loss. it's not a GLP-1. it's amylin — the hormone your pancreas releases alongside insulin every time you eat. it's what tells your brain you're full. GLP-1 drugs hit one appetite pathway. amylin hits a different one. they ran https://t.co/1Xp6aiGu5b

I'm part of the golden generation of peptides. When I tell people I'm building in this space, the first thing they ask is whether I take them myself. I don't, and the reason is simple: I don't need them yet. I'm 22 years old. I don't need Retatrutide, I'm not trying to get https://t.co/tPveqQZZj7

The Wolverine stack. What is it? This is a equal combination of BPC-157 and TB-500, two peptides that are not FDA approved but were recommended by the FDA's Pharmacy Compounding Advisory Committee for addition to the 503A bulk list. The 503A bulk list is a list of drugs that

Peptide cheat sheet (by route) Injectables (subQ) + BPC-157 (healing, gut) + TB-500 (injury recovery) + CJC-1295 + Ipamorelin (growth hormone) + Retatrutide (fat loss) + MOTS-c (metabolism, energy) Nasal sprays + Semax (focus) + Selank (calm) + PT-141 (libido) Oral / capsule +